Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27789110 | 0.83 | KDM4E (0.51) | KDM4EGPR183KMT2AMEN1ALDH1A1 | |
| SCHEMBL28263285 | 0.82 | KDM4E (0.54) | KDM4EGPR183KMT2AMEN1DRD3 | |
| SCHEMBL10263815 | 0.82 | PIK3CD (0.52) | KDM4EGPR183KMT2AMEN1ALDH1A1 | |
| SCHEMBL21152530 | 0.80 | KDM4E (0.49) | KDM4EGPR183KMT2AMEN1POLB | |
| SCHEMBL20621109 | 0.80 | KDM4E (0.56) | KDM4EGPR183KMT2AMEN1ALDH1A1 | |
| SCHEMBL3967519 | 0.79 | HRH3 (0.47) | — | |
| SCHEMBL15348806 | 0.78 | KDM4E (0.42) | KDM4EGPR183KMT2AMEN1ALDH1A1 | |
| SCHEMBL11575106 | 0.78 | — | — | |
| SCHEMBL19369090 | 0.77 | KDM4E (0.46) | KDM4EGPR183KMT2AMEN1ALDH1A1 | |
| SCHEMBL20962683 | 0.77 | KDM4E (0.54) | KDM4EGPR183KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | KDM4E 2506/4885GPR183 2727/4885KMT2A 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.